Penn Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Penn Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,893	Closed	-$9.18M	–	294
2016 Q1	$9.18M	Sell	2,893 -75	-3%	-$311K	0.52%	73
2015 Q4	$15.2M	Buy	2,968 +335	+13%	+$1.46M	0.67%	46
2015 Q3	$8.38M	Sell	2,633 -619	-19%	-$2.4M	0.44%	87
2015 Q2	$13M	Sell	3,252 -306	-9%	-$1.18M	0.54%	62
2015 Q1	$14.2M	Buy	3,558 +26	+0.7%	+$119K	0.56%	62
2014 Q4	$17.3M	Sell	3,532 -2,172	-38%	-$9.32M	0.73%	33
2014 Q3	$23.2M	Buy	5,704 +787	+16%	+$2.95M	0.97%	19
2014 Q2	$19.9M	Buy	4,917 +2,078	+73%	+$8.47M	0.77%	38
2014 Q1	$12.9M	Buy	+2,839	New	+$11.5M	0.49%	77

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Penn Capital Management's ACOR Position: Q2 2016 in Review

Penn Capital Management sold out of Acorda Therapeutics (ACOR) in Q2 2016, closing a stake of 2,893 shares — an estimated $9.18M sold.

Penn Capital Management first reported a position in ACOR in Q1 2014 and held it in 9 quarters. The position peaked at $23.2M in Q3 2014. 175 funds tracked by Wall St. Rank hold ACOR as of Q2 2016.

Penn Capital Management reported no remaining Acorda Therapeutics position as of Q2 2016 after selling out during the quarter.
Penn Capital Management sold 2,893 Acorda Therapeutics shares in Q2 2016, an estimated $9.18M.
Penn Capital Management first reported a position in Acorda Therapeutics in Q1 2014 and held it in 9 quarters.
Penn Capital Management's Acorda Therapeutics position peaked at $23.2M in Q3 2014.
175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2016.

Based on Penn Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.